Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Craving and opioid use disorder: A scoping review.

Kleykamp BA, De Santis M, Dworkin RH, Huhn AS, Kampman KM, Montoya ID, Preston KL, Ramey T, Smith SM, Turk DC, Walsh R, Weiss RD, Strain EC.

Drug Alcohol Depend. 2019 Dec 1;205:107639. doi: 10.1016/j.drugalcdep.2019.107639. Epub 2019 Oct 17. Review.

PMID:
31683241
2.

The treatment of cocaine use disorder.

Kampman KM.

Sci Adv. 2019 Oct 16;5(10):eaax1532. doi: 10.1126/sciadv.aax1532. eCollection 2019 Oct. Review.

3.

The Relationship between Alcohol Craving and Insomnia Symptoms in Alcohol-Dependent Individuals.

He S, Brooks AT, Kampman KM, Chakravorty S.

Alcohol Alcohol. 2019 May 1;54(3):287-294. doi: 10.1093/alcalc/agz029.

4.

Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder.

Crist RC, Phillips KA, Furnari MA, Moran LM, Doyle GA, McNicholas LF, Cornish JW, Kampman KM, Preston KL, Berrettini WH.

Pharmacogenomics J. 2019 Jun;19(3):260-268. doi: 10.1038/s41397-018-0065-x. Epub 2018 Oct 27.

5.

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S.

JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052.

6.

Adverse effects of marijuana use.

Feeney KE, Kampman KM.

Linacre Q. 2016 May;83(2):174-178.

7.

Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues.

Regier PS, Monge ZA, Franklin TR, Wetherill RR, Teitelman A, Jagannathan K, Suh JJ, Wang Z, Young KA, Gawrysiak M, Langleben DD, Kampman KM, O'Brien CP, Childress AR.

Addict Biol. 2017 Nov;22(6):1768-1777. doi: 10.1111/adb.12445. Epub 2016 Sep 22.

8.

A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment.

Crist RC, Doyle GA, Kampman KM, Berrettini WH.

Drug Alcohol Depend. 2016 Sep 1;166:268-71. doi: 10.1016/j.drugalcdep.2016.07.008. Epub 2016 Jul 14.

9.

Attitudes Toward Treating Addiction With Deep Brain Stimulation.

Ali R, DiFrancesco MF, Ho AL, Kampman KM, Caplan AL, Halpern CH.

Brain Stimul. 2016 May-Jun;9(3):466-468. doi: 10.1016/j.brs.2016.03.009. Epub 2016 Mar 15. No abstract available.

PMID:
27066935
10.

A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C, O'Brien CP.

Drug Alcohol Depend. 2015 Oct 1;155:105-10. doi: 10.1016/j.drugalcdep.2015.08.005. Epub 2015 Aug 14.

11.

Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity.

Chaudhary NS, Kampman KM, Kranzler HR, Grandner MA, Debbarma S, Chakravorty S.

Addict Behav. 2015 Nov;50:165-72. doi: 10.1016/j.addbeh.2015.06.021. Epub 2015 Jun 20.

12.

A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.

Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, O'Brien CP.

Am J Addict. 2014 Nov-Dec;23(6):591-7. doi: 10.1111/j.1521-0391.2014.12146.x. Epub 2014 Sep 22.

PMID:
25251201
13.

Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, Chartier K, Kampman KM, Sharma G, Lewis DF, VanVeldhuisen P, Theobald J, May J, Brigham GS.

J Clin Psychiatry. 2014 Jul;75(7):757-64. doi: 10.4088/JCP.13m08862.

14.

The effects of quetiapine on sleep in recovering alcohol-dependent subjects: a pilot study.

Chakravorty S, Hanlon AL, Kuna ST, Ross RJ, Kampman KM, Witte LM, Perlis ML, Oslin DW.

J Clin Psychopharmacol. 2014 Jun;34(3):350-4. doi: 10.1097/JCP.0000000000000130.

PMID:
24747978
15.

Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues.

Young KA, Franklin TR, Roberts DC, Jagannathan K, Suh JJ, Wetherill RR, Wang Z, Kampman KM, O'Brien CP, Childress AR.

J Neurosci. 2014 Apr 2;34(14):5038-43. doi: 10.1523/JNEUROSCI.4977-13.2014.

16.

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM.

Am J Psychiatry. 2014 Apr;171(4):445-52. doi: 10.1176/appi.ajp.2013.13081014. Erratum in: Am J Psychiatry. 2014 May 1;171(5):585.

17.

The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.

Clarke TK, Weiss AR, Ferarro TN, Kampman KM, Dackis CA, Pettinati HM, O'brien CP, Oslin DW, Lohoff FW, Berrettini WH.

Ann Hum Genet. 2014 Jan;78(1):33-9. doi: 10.1111/ahg.12046. Epub 2013 Nov 25.

18.

Biomarkers for the development of new medications for cocaine dependence.

Bough KJ, Amur S, Lao G, Hemby SE, Tannu NS, Kampman KM, Schmitz JM, Martinez D, Merchant KM, Green C, Sharma J, Dougherty AH, Moeller FG.

Neuropsychopharmacology. 2014 Jan;39(1):202-19. doi: 10.1038/npp.2013.210. Epub 2013 Aug 27. Review.

19.

Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence.

Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM.

Drug Alcohol Depend. 2013 Dec 1;133(2):754-8. doi: 10.1016/j.drugalcdep.2013.06.019. Epub 2013 Jul 31.

20.

A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence.

Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O'Brien CP.

Drug Alcohol Depend. 2013 Nov 1;133(1):94-9. doi: 10.1016/j.drugalcdep.2013.05.026. Epub 2013 Jun 28.

21.

Case-control association study of WLS variants in opioid and cocaine addicted populations.

Crist RC, Ambrose-Lanci LM, Zeng A, Yuan C, Kampman KM, Pettinati HM, Oslin DW, O'Brien CP, Ferraro TN, Doyle GA, Lohoff FW, Berrettini WH.

Psychiatry Res. 2013 Jun 30;208(1):62-6. doi: 10.1016/j.psychres.2013.03.011. Epub 2013 Apr 5.

22.

Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.

Clarke TK, Crist RC, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Ferraro TN, Lohoff FW, Berrettini WH.

Neurosci Lett. 2013 May 10;542:71-5. doi: 10.1016/j.neulet.2013.02.018. Epub 2013 Feb 20.

23.

Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European Americans.

Multani PK, Clarke TK, Narasimhan S, Ambrose-Lanci L, Kampman KM, Pettinati HM, Oslin DW, O'Brien CP, Berrettini WH, Lohoff FW.

Neurosci Lett. 2012 Nov 30;531(1):46-51. doi: 10.1016/j.neulet.2012.09.014. Epub 2012 Sep 20.

24.

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.

Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Doyle GA, Lohoff FW, Berrettini WH.

Drug Alcohol Depend. 2013 Jan 1;127(1-3):122-8. doi: 10.1016/j.drugalcdep.2012.06.023. Epub 2012 Jul 12.

25.

Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction.

Clarke TK, Ambrose-Lanci L, Ferraro TN, Berrettini WH, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Lohoff FW.

Genes Brain Behav. 2012 Jun;11(4):415-23. doi: 10.1111/j.1601-183X.2012.00785.x. Epub 2012 Apr 11.

26.

A double-blind, placebo-controlled trial of modafinil for cocaine dependence.

Dackis CA, Kampman KM, Lynch KG, Plebani JG, Pettinati HM, Sparkman T, O'Brien CP.

J Subst Abuse Treat. 2012 Oct;43(3):303-12. doi: 10.1016/j.jsat.2011.12.014. Epub 2012 Feb 27.

27.

Expanding applications of deep brain stimulation: a potential therapeutic role in obesity and addiction management.

Halpern CH, Torres N, Hurtig HI, Wolf JA, Stephen J, Oh MY, Williams NN, Dichter MA, Jaggi JL, Caplan AL, Kampman KM, Wadden TA, Whiting DM, Baltuch GH.

Acta Neurochir (Wien). 2011 Dec;153(12):2293-306. doi: 10.1007/s00701-011-1166-3. Review.

PMID:
21976235
28.

Results of an initial clinical trial of varenicline for the treatment of cocaine dependence.

Plebani JG, Lynch KG, Yu Q, Pettinati HM, O'Brien CP, Kampman KM.

Drug Alcohol Depend. 2012 Feb 1;121(1-2):163-6. doi: 10.1016/j.drugalcdep.2011.08.025. Epub 2011 Sep 16.

29.

Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis.

Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, Kampman KM, Baltuch GH, Caplan AL, Stein SC.

Addiction. 2012 Mar;107(3):624-34. doi: 10.1111/j.1360-0443.2011.03656.x. Review.

PMID:
21919988
30.

Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis.

Clarke TK, Bloch PJ, Ambrose-Lanci LM, Ferraro TN, Berrettini WH, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Lohoff FW.

Addict Biol. 2013 Jul;18(4):702-8. doi: 10.1111/j.1369-1600.2011.00346.x. Epub 2011 Jul 25.

31.

A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence.

Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O'Brien CP.

Addict Behav. 2011 Mar;36(3):217-21. doi: 10.1016/j.addbeh.2010.11.003. Epub 2010 Nov 10.

32.

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL.

JAMA. 2010 Oct 13;304(14):1576-83. doi: 10.1001/jama.2010.1427.

PMID:
20940383
33.

Covariates of craving in actively drinking alcoholics.

Chakravorty S, Kuna ST, Zaharakis N, O'Brien CP, Kampman KM, Oslin D.

Am J Addict. 2010 Sep-Oct;19(5):450-7. doi: 10.1111/j.1521-0391.2010.00067.x.

34.

What's new in the treatment of cocaine addiction?

Kampman KM.

Curr Psychiatry Rep. 2010 Oct;12(5):441-7. doi: 10.1007/s11920-010-0143-5. Review.

PMID:
20697850
35.

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.

Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP.

Am J Psychiatry. 2010 Jun;167(6):668-75. doi: 10.1176/appi.ajp.2009.08060852. Epub 2010 Mar 15.

36.

Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence.

Lohoff FW, Bloch PJ, Hodge R, Nall AH, Ferraro TN, Kampman KM, Dackis CA, O'Brien CP, Pettinati HM, Oslin DW.

Neurosci Lett. 2010 Apr 5;473(2):87-91. doi: 10.1016/j.neulet.2010.02.021. Epub 2010 Feb 17.

PMID:
20170711
37.

Tolerance and sensitization to the effects of cocaine use in humans: a retrospective study of long-term cocaine users in Philadelphia.

Small AC, Kampman KM, Plebani J, De Jesus Quinn M, Peoples L, Lynch KG.

Subst Use Misuse. 2009;44(13):1888-98. doi: 10.3109/10826080902961179.

PMID:
20001286
38.

Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence.

Plebani JG, Tirado CF, Pettinati HM, Kampman KM, Volpicelli JR, Oslin DW.

Addict Behav. 2010 Feb;35(2):123-8. doi: 10.1016/j.addbeh.2009.09.012. Epub 2009 Sep 10.

39.

New medications for the treatment of cocaine dependence.

Kampman KM.

Ann Ist Super Sanita. 2009;45(2):109-15. Review. No abstract available.

40.

Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence.

Bloch PJ, Nall AH, Weller AE, Ferraro TN, Berrettini WH, Kampman KM, Pettinati HM, Dackis CA, O'Brien CP, Oslin DW, Lohoff FW.

Psychiatr Genet. 2009 Oct;19(5):275-6. doi: 10.1097/YPG.0b013e32832cec12. No abstract available.

41.

Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence.

Lohoff FW, Bloch PJ, Ferraro TN, Berrettini WH, Pettinati HM, Dackis CA, O'Brien CP, Kampman KM, Oslin DW.

Neurosci Lett. 2009 Apr 10;453(3):199-203. doi: 10.1016/j.neulet.2009.02.026. Epub 2009 Feb 21.

42.

Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence.

Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin DW, Sparkman T, Sharkoski T, O'Brien CP.

Addict Behav. 2009 Jun-Jul;34(6-7):581-6. doi: 10.1016/j.addbeh.2009.03.014. Epub 2009 Mar 24.

43.

Early abstinence in cocaine pharmacotherapy trials predicts successful treatment outcomes.

Plebani JG, Kampman KM, Lynch KG.

J Subst Abuse Treat. 2009 Oct;37(3):313-7. doi: 10.1016/j.jsat.2009.02.001. Epub 2009 Mar 31.

44.

Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment.

Ahmadi J, Kampman KM, Oslin DM, Pettinati HM, Dackis C, Sparkman T.

Am J Addict. 2009 Jan-Feb;18(1):81-6. doi: 10.1080/10550490802545174.

45.

Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence.

Suh JJ, Pettinati HM, Kampman KM, O'Brien CP.

Am J Addict. 2008 Nov-Dec;17(6):463-8. doi: 10.1080/10550490802409074.

46.

Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial.

Fairbairn CE, Dundon WD, Xie H, Plebani JG, Kampman KM, Lynch KG.

Am J Addict. 2008 Sep-Oct;17(5):387-91. doi: 10.1080/10550490802266078.

47.

Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence.

Lohoff FW, Weller AE, Bloch PJ, Nall AH, Ferraro TN, Kampman KM, Pettinati HM, Oslin DW, Dackis CA, O'Brien CP, Berrettini WH.

Neuropsychopharmacology. 2008 Dec;33(13):3078-84. doi: 10.1038/npp.2008.126. Epub 2008 Aug 13.

48.

Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence.

Lohoff FW, Bloch PJ, Weller AE, Nall AH, Doyle GA, Buono RJ, Ferraro TN, Kampman KM, Pettinati HM, Dackis CA, Oslin DW, O'Brien CP, Berrettini WH.

Neurosci Lett. 2008 Aug 8;440(3):280-3. doi: 10.1016/j.neulet.2008.05.073. Epub 2008 May 24.

49.

A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.

Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, Ten Have T, Wortman S, Dundon W, Dackis C, Volpicelli JR, O'Brien CP.

Alcohol Clin Exp Res. 2008 Jul;32(7):1299-308. doi: 10.1111/j.1530-0277.2008.00698.x.

50.

The search for medications to treat stimulant dependence.

Kampman KM.

Addict Sci Clin Pract. 2008 Jun;4(2):28-35.

Supplemental Content

Loading ...
Support Center